VTRS
NASDAQ
Pharmaceuticals
$17.29
USD
-$0.04 (-0.23%)
At close: Jul 17, 2026, 4:00 PM EDT
Market Cap:
$20.34B
Volume:
9.5M
Previous Close
$17.33
Day Range
$17.23 - $17.67
52 Week Range
$8.63 - $17.67
Average Volume (10 Days)
8.9M
P/E Ratio (TTM)
—
Dividend Yield
2.74%
Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 30,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.
CEO
Mr. Scott Smith
Headquaters
Canonsburg, PENNSYLVANIA, US
Founded
1973
Employees
30,000
Viatris has voluntarily recalled one lot of Xanax XR 3mg extended-release tablets (lot 8177156) after the pills failed dissolution tests, meaning they may not break down and release medication as intended. The FDA classified this as a Class II recall, indicating low risk of serious harm. Only 51 bottles were distributed, and no adverse events have been reported.
0
0